Webinar: Streamlining the Regulatory Process to Advance Access to Biosimilars

This webinar celebrating Global Biosimilars Week 2024 was hosted by The Center for Biosimilars^® in partnership with the International Generics and Biosimilars Association.

Global Biosimilars Week (GBW) 2024 is an annual campaign designed to raise global awareness about biosimilar medicines and their role in improving patient care and access to affordable treatment options.

This year’s theme, "Advancing Access to Biosimilars," focuses on the progress made over the past two decades surrounding approval, market acceptance and adoption of biosimilars—as well as the challenges that remain in expanding access worldwide. With an effort to highlight the importance of collaboration among health care professionals, patients, stakeholders, and policymakers, the webinar will focus on Streamlining Regulatory Requirements to advance access to biosimilars and will feature expert discussions on the key barriers to biosimilar uptake in different regions and explore strategies to overcoming these obstacles.

Key Takeaways:

• Current global trends in streamlining biosimilar regulatory requirements to foster efficient adoption and market growth.
• Strategies to address challenges and improve biosimilar access.
• The role of biosimilars in promoting health care sustainability and better patient outcomes.

Speakers

Skylar Jeremias, assistant managing editor of The Center for Biosimilars (host)

Giuseppe Randazzo, senior vice president of sciences and regulatory affairs, Association for Accessible Medicines (moderator)

Ali Alhomaidan, PhD, Executive Director for Products Evaluation and Standards Setting, Saudi Food and Drug Authority

Ivana Knezevic, PhD, scientist, technical standards and specification unit group lead, norms and standards for biologicals, Health Product Policy and Standards/Medicines and Health Products/World Health Organization

Peter Richardson, PhD, senior quality specialist, European Medicines Agency

Sarah Yim, MD, director, Office of Therapeutic Biologics and Biosimilars Office of New Drugs, Center for Drug Evaluation and Research, FDA